Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 5;50(W1):W739-W743.
doi: 10.1093/nar/gkac382.

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples

Aleksandr Ianevski  1   2 , Anil K Giri  1   3 , Tero Aittokallio  1   2   4   5
Affiliations

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples

Aleksandr Ianevski et al. Nucleic Acids Res. .

Abstract

SynergyFinder (https://synergyfinder.fimm.fi) is a free web-application for interactive analysis and visualization of multi-drug combination response data. Since its first release in 2017, SynergyFinder has become a popular tool for multi-dose combination data analytics, partly because the development of its functionality and graphical interface has been driven by a diverse user community, including both chemical biologists and computational scientists. Here, we describe the latest upgrade of this community-effort, SynergyFinder release 3.0, introducing a number of novel features that support interactive multi-sample analysis of combination synergy, a novel consensus synergy score that combines multiple synergy scoring models, and an improved outlier detection functionality that eliminates false positive results, along with many other post-analysis options such as weighting of synergy by drug concentrations and distinguishing between different modes of synergy (potency and efficacy). Based on user requests, several additional improvements were also implemented, including new data visualizations and export options for multi-drug combinations. With these improvements, SynergyFinder 3.0 supports robust identification of consistent combinatorial synergies for multi-drug combinatorial discovery and clinical translation.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.
Figure 1.
Figure 1.
Novel features implemented in the SynergyFinder version 3.0 include (A) multi-sample analysis with interactive visualization of combination effects across the samples, (B) Bliss/Loewe consensus scoring to eliminate false positive synergy results (in the example case, user-selected HSA model identifies moderate-to-strong synergy, whereas Bliss/Loewe consensus suggests a strong antagonism, indicating low-confidence HSA synergy), (C) multiple post-analysis options, such as distinguishing between different modes of synergy (potency and efficacy), and prioritizing of combinations that show maximal synergy at lower doses (the dotted box). (D) An example of how SynergyFinder highlights combinations that show synergy at lower dose windows by weighting synergy at each dose level according to the proportion of response values of single-agents at these doses (see text for details).
See this image and copyright information in PMC

References

    1. Mancia G., Rea F., Corrao G., Grassi G.. Two-drug combinations as first-step antihypertensive treatment. Circ. Res. 2019; 124:1113–1123. - PubMed
    1. Thoueille P., Choong E., Cavassini M., Buclin T., Decosterd L.A.. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J. Antimicrob. Chemother. 2022; 77:290–302. - PMC - PubMed
    1. Davies G., Boeree M., Hermann D., Hoelscher M.. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. PLoS Med. 2019; 16:e1002851. - PMC - PubMed
    1. Kurtz S.E., Eide C.A., Kaempf A., Khanna V., Savage S.L., Rofelty A., English I., Ho H., Pandya R.et al. .. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc. Natl. Acad. Sci. U.S.A. 2017; 114:E7554–E7563. - PMC - PubMed
    1. Ianevski A., Lahtela J., Javarappa K.K., Sergeev P., Ghimire B.R., Gautam P., Vähä-Koskela M., Turunen L., Linnavirta N., Kuusanmäki H.et al. .. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Sci. Adv. 2021; 7:eabe4038. - PMC - PubMed

Publication types

Substances